Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ASMB logo ASMB
Upturn stock ratingUpturn stock rating
ASMB logo

Assembly Biosciences Inc (ASMB)

Upturn stock ratingUpturn stock rating
$13.8
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/03/2025: ASMB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $30

Year Target Price $30

Analyst’s Price TargetsFor last 52 week
$30Target price
Low$7.75
Current$13.8
high$19.93

Analysis of Past Performance

Type Stock
Historic Profit -46.62%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 132.21M USD
Price to earnings Ratio -
1Y Target Price 30
Price to earnings Ratio -
1Y Target Price 30
Volume (30-day avg) -
Beta 0.55
52 Weeks Range 7.75 - 19.93
Updated Date 06/29/2025
52 Weeks Range 7.75 - 19.93
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.2

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -124.15%
Operating Margin (TTM) -105.54%

Management Effectiveness

Return on Assets (TTM) -25.49%
Return on Equity (TTM) -133.65%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 44198042
Price to Sales(TTM) 4.11
Enterprise Value 44198042
Price to Sales(TTM) 4.11
Enterprise Value to Revenue 1.37
Enterprise Value to EBITDA 0.42
Shares Outstanding 7637550
Shares Floating 4637980
Shares Outstanding 7637550
Shares Floating 4637980
Percent Insiders 39.25
Percent Institutions 12.77

Analyst Ratings

Rating 5
Target Price 30
Buy -
Strong Buy 2
Buy -
Strong Buy 2
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Assembly Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Assembly Biosciences, Inc. was founded in 2005. It is a biotechnology company focused on developing novel therapeutics targeting hepatitis B virus (HBV) infection. The company has evolved through various phases of research and clinical development, focusing on core inhibitor and viral entry inhibitor programs.

business area logo Core Business Areas

  • HBV Program: Assembly Biosciences focuses on developing and commercializing direct acting antiviral therapeutics for the treatment of HBV infection. This includes developing core inhibitors and other potential HBV therapies.

leadership logo Leadership and Structure

The leadership team consists of the CEO, CFO, Chief Medical Officer, and other key executives. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical development, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Vebicorvir (ABI-H0731): Vebicorvir is a core inhibitor being developed for the treatment of chronic HBV infection. Its market potential depends on its clinical success and eventual approval. Competitors include other HBV therapeutics from companies like Gilead Sciences and Roche.
  • ABI-4334: An oral HBV surface antigen (HBsAg) secretion inhibitor. Competitors include other HBV therapeutics from companies like Gilead Sciences and Roche.

Market Dynamics

industry overview logo Industry Overview

The industry is characterized by a significant unmet need for effective HBV therapies, driving intense competition and innovation. The Hepatitis B market consists of nucleos(t)ide analogues and interferon injections. Development of curative therapy is a major focus.

Positioning

Assembly Biosciences is positioned as a company focused on developing novel core inhibitors for HBV, aiming to achieve functional cures. Their competitive advantage lies in the potential efficacy and safety profile of their core inhibitors and HBsAg inhibitors.

Total Addressable Market (TAM)

The global market for Hepatitis B therapeutics is estimated to be several billion dollars. Assembly Biosciences is positioned to capture a portion of this TAM with successful development and commercialization of their pipeline assets. Exact TAM figures vary depending on the source but are in the $3-5 billion range globally.

Upturn SWOT Analysis

Strengths

  • Novel Core Inhibitor Technology
  • Experienced Management Team
  • Targeting a Large Unmet Medical Need
  • Strong Intellectual Property Portfolio

Weaknesses

  • Reliance on Pipeline Success
  • Limited Commercial Infrastructure
  • Competition from Established Players
  • High R&D Expenditure

Opportunities

  • Partnerships with Larger Pharmaceutical Companies
  • Expansion into Other Viral Diseases
  • Advancements in HBV Diagnostics
  • Favorable Regulatory Environment

Threats

  • Clinical Trial Failures
  • Regulatory Hurdles
  • Competition from Novel Therapies
  • Pricing Pressures

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • ROCHE.SW
  • ABUS

Competitive Landscape

Assembly Biosciences faces competition from established pharmaceutical companies with approved HBV therapies. Assembly Biosciences' advantage comes from a potential for curative therapies and has novel technology

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been largely driven by clinical trial progress and partnerships.

Future Projections: Future growth projections are contingent on clinical trial outcomes, regulatory approvals, and commercial success.

Recent Initiatives: Recent initiatives include advancing clinical trials of core inhibitors and HBsAg inhibitors, and forming partnerships to expand development efforts.

Summary

Assembly Biosciences is a biotechnology company focusing on HBV therapies with innovative approaches. Its success heavily relies on the clinical trial outcomes of its core inhibitor and HBsAg inhibitor programs. While facing competition from established giants, the companyu2019s novel technology offers potential advantages. Monitoring trial results and securing partnerships are crucial for their future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Assembly Biosciences Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2010-12-17
CEO, President & Director Mr. Jason A. Okazaki J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 73
Full time employees 73

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.